GSK, GB00BN7SWP63

GSK stock: Shares trade 0.14% above Xetra close

Published on 11/19/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK stock is in focus after US regulators cleared Nelkarmi for ALK-positive lung cancer. The decision came ahead of the FDA's November 27 target date.

Key points for investors

  • The FDA granted accelerated approval for Nelkarmi in previously treated ALK-positive non-small cell lung cancer.
  • The approval was based on phase I/II ALKOVE-1 results and came ahead of the original FDA target date.
  • GSK's oncology portfolio remains central as investors assess future growth and treatment risks.
GSK, GB00BN7SWP63, Illustration mit AI erstellt.

GSK stock traded at 21.87 euros on Lang & Schwarz at 17:44 CET on Thursday, November 19, 2026, 0.14 percent above the Xetra close of 21.84 euros on Thursday, November 19. The euro-denominated quote was 2.89 percent below the 22.52 euros cited in the previous GSK report on November 18 at 12:08 CET.

Regulatory backdrop remains relevant

On November 17, GSK announced that the US Food and Drug Administration had granted accelerated approval to Nelkarmi, also known as neladalkib, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who had received prior treatment. The indication covers patients previously treated with alectinib or with at least two ALK tyrosine kinase inhibitors and platinum-based chemotherapy, according to GSK's announcement.

The decision came ahead of the FDA's original November 27 target action date. GSK described Nelkarmi as its second new medicine approved in lung cancer this year, adding to the importance of oncology execution within the group's growth strategy.

Clinical data and investor focus

The approval relied on results from the phase I/II ALKOVE-1 trial. GSK said the confirmed overall response rate was 49 percent among patients whose only prior ALK tyrosine kinase inhibitor was alectinib and 32 percent among patients who had received at least two prior ALK inhibitors and chemotherapy.

The accelerated approval is based on tumor response rate and duration of response. Continued approval may depend on confirmation and description of clinical benefit in a confirmatory study, leaving further clinical evidence as an important point for investors.

GSK plc stock facts

  • Company: GSK plc
  • ISIN: GB00BN7SWP63
  • Lang & Schwarz quote: 21.87 euros on Thursday, November 19, 2026, at 17:44 CET
  • Xetra close: 21.84 euros on Thursday, November 19, 2026
  • Daily comparison: 0.14 percent above the Xetra close

Broader European trading context is covered in Current market reports.

More news and analyses on GSK stock

Disclaimer...
en | GB00BN7SWP63 | GSK | boerse | 70537375 | bgmi